EDN1 and Stroke: The latter are particularly sensitive to ET-1 and provide the therapeutic rationale for blocking the actions of the peptide, which is thought to be a mediator of cerebrovascular disorders including delayed vasospasm associated with subarachnoid hemorrhage and stroke.